Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock suffered a major decline of -11.7% on 7/29/24. The shares closed at $5.05. However, trading volume in this decline was below average at 71% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -14.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, EGRX is expected to continue to be a modest Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Eagle Pharmaceuticals has a very high Appreciation Score of 98 but a very low Power Rating of 14, leading to the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment